Altium Capital Management

Altium Capital Management is a private equity firm specializing in healthcare investments. The firm focuses on providing growth capital to private and public companies developing novel technologies for human health. Their investment universe is primarily concentrated in therapeutics, targeting private ventures, small-cap, and micro-cap public companies. Altium seeks companies with transformative catalysts in the years to come, many of which are raising capital from institutional investors for the first time. The firm supports early-stage ventures in the pre-clinical development phases, aiming for long-term partnerships and multiple rounds of financing into those firms. Altium also helps companies attract additional capital through its network of like-minded investors. Their research and due diligence give them the confidence to invest long-term in promising new technologies. Altium Capital Management was founded in 2017 by Jacob Gottlieb, MD, CFA, PRM, who serves as the Managing Partner and Chief Investment Officer. Dr. Gottlieb has over 20 years of experience in hedge fund, private equity, and venture capital investing, including developing successful teams of investment professionals and business management staff. Prior to founding Altium, Dr. Gottlieb founded Visium Asset Management in 2005, which grew to approximately $8 billion in assets under management. Under his leadership, Visium became one of the premier healthcare investors in the world, managing assets for public and private pension funds, corporate investment offices, endowments and foundations, and ultra-high-net-worth families. Dr. Gottlieb graduated magna cum laude from Brown University and earned his medical degree from New York University Medical School in 1997. He obtained his CFA charter in 2001 and his PRM designation from the Professional Risk Managers' International Association in 2010. Altium Capital Management's portfolio includes several notable companies, such as Antios Therapeutics, Cerevel Therapeutics, Chemomab Therapeutics, eGenesis, Gemini Therapeutics, Hummingbird Bioscience, Hyperfine, Immunovant, Ocuphire Pharma, Palisade Bio, Quoin, Sagimet Biosciences, Seelos Therapeutics, Sonnet BioTherapeutics, Timber Pharmaceuticals, Vincerx Pharma, and Yumanity Therapeutics. These companies are involved in various aspects of healthcare, including biopharmaceuticals, biotechnology, medical devices, and healthcare services. Altium Capital Management is headquartered in New York, NY, and operates with a team that includes a mix of scientific professionals and experienced fund managers who work together to uncover unique investment insights to produce superior returns in the long term. The firm's core values are teamwork, continuous improvement, and integrity, with a team that combines medical, scientific, and industry experts working with professional investors to make informed investment decisions.